Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | recruiting | Phase 1 | 36 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | recruiting | Phase 1 / Phase 2 | 200 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | recruiting | Phase 1 | 320 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT07719361 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 60 | Flare Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07824934 | HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 110 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | recruiting | Phase 1 | 300 | National Cancer Institute (NCI)NIH | 2 | Sep 23, 2026 | clinicaltrials |
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04301076 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | recruiting | Phase 1 / Phase 2 | 150 | Disc Medicine, IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | recruiting | Phase 1 / Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06088004 | Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 218 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06102902 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | recruiting | Phase 1 | 32 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06308588 | Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06389591 | RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) | recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06619587 | A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 410 | Genentech, Inc.INDUSTRY | 11 | Sep 23, 2026 | clinicaltrials |
| NCT06915753 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations(SURF431) | recruiting | Phase 1 | 125 | Tyra Biosciences, IncINDUSTRY | 4 | Sep 23, 2026 | clinicaltrials |
| NCT06926283 | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06999798 | An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07012044 | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | recruiting | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 190 | ModernaTX, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07136142 | A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07140016 | A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 1 | 40 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | recruiting | Phase 1 / Phase 2 | 198 | Bristol-Myers SquibbINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | recruiting | Phase 1 / Phase 2 | 474 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 23, 2026 | clinicaltrials |
| NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors(OP-NEU-101) | recruiting | Phase 1 / Phase 2 | 275 | Onchilles Pharma IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07537881 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 326 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07800936 | HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors | recruiting | Phase 1 | 44 | Parr Biotechnology (Hebei) Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07822919 | A Study of AWT020 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 96 | Anwita BiosciencesINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03366116 | 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | recruiting | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04855656 | Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors(MYTHIC) | recruiting | Phase 1 | 464 | Debiopharm International SAINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 116 | Debiopharm International SAINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,130 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06465316 | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | recruiting | Phase 1 | 65 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06771219 | SLV-154 Treatment of Advanced Cancers | recruiting | Phase 1 | 250 | Solve TherapeuticsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )(BAF_FRontier-1) | recruiting | Phase 1 | 215 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT07117032 | Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain | recruiting | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | recruiting | Phase 1 | 460 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 22, 2026 | clinicaltrials |
| NCT07228247 | A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07262619 | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | recruiting | Phase 1 / Phase 2 | 160 | Eikon TherapeuticsINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials